open access

Vol 66, No 3 (2015)
Original papers
Published online: 2015-07-01
Submitted: 2014-07-01
Accepted: 2014-08-12
Get Citation

Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.

Robert Krysiak, Anna Gdula-Dymek, Bogdan Marek, Bogusław Okopień
DOI: 10.5603/EP.2015.0029
·
Endokrynologia Polska 2015;66(3):224-230.

open access

Vol 66, No 3 (2015)
Original papers
Published online: 2015-07-01
Submitted: 2014-07-01
Accepted: 2014-08-12

Abstract

Introduction: Statins and fibrates reduce monocyte release of proinflammatory cytokines, but it remains unknown whether this effect is sex dependent.

Material and methods: We retrospectively analysed age-, weight-, and lipid-matched populations of type 2 diabetic patients of both sexes, who, because of atherogenic dyslipidaemia, were treated with simvastatin (40 mg daily), fenofibrate (200 mg daily), or simvastatin plus fenofibrate. Monocyte release of tumour necrosis factor alpha (TNF-alpha), inteleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 (MCP-1), as well as circulating levels of high-sensitivity C-reactive protein (hsCRP) and free fatty acids (FFA) were assessed separately for men and women before and after 12 weeks of treatment.

Results: Baseline monocyte release of TNF-alpha, interleukin-1beta, interleukin-6, and MCP-1, as well as plasma hsCRP and FFA levels were comparable in both sexes. Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced monocyte release of TNF-alpha, inteleukin-1beta, interleukin-6, and MCP-1, with no difference between the treatment groups. The impact of simvastatin and fenofibrate administered alone on monocyte cytokine release and systemic inflammation did not differ between the men and women. The effect of simvastatin/fenofibrate combination therapy on monocyte release of interleukin-6 and MCP-1 was more pronounced in the male population. The impact of simvastatin administered together with fenofibrate on TNF-alpha, interleukin-1beta, and hsCRP was also stronger in the men than in the women, but the difference did not reach the level of significance.

Conclusions: The obtained results suggest that sex differences determine the strength of the monocyte-suppressing effect of simvastatin/ /fenofibrate combination therapy in type 2 diabetic patients with atherogenic dyslipidaemia. (Endokrynol Pol 2015; 66 (3): 224–230)

Abstract

Introduction: Statins and fibrates reduce monocyte release of proinflammatory cytokines, but it remains unknown whether this effect is sex dependent.

Material and methods: We retrospectively analysed age-, weight-, and lipid-matched populations of type 2 diabetic patients of both sexes, who, because of atherogenic dyslipidaemia, were treated with simvastatin (40 mg daily), fenofibrate (200 mg daily), or simvastatin plus fenofibrate. Monocyte release of tumour necrosis factor alpha (TNF-alpha), inteleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 (MCP-1), as well as circulating levels of high-sensitivity C-reactive protein (hsCRP) and free fatty acids (FFA) were assessed separately for men and women before and after 12 weeks of treatment.

Results: Baseline monocyte release of TNF-alpha, interleukin-1beta, interleukin-6, and MCP-1, as well as plasma hsCRP and FFA levels were comparable in both sexes. Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced monocyte release of TNF-alpha, inteleukin-1beta, interleukin-6, and MCP-1, with no difference between the treatment groups. The impact of simvastatin and fenofibrate administered alone on monocyte cytokine release and systemic inflammation did not differ between the men and women. The effect of simvastatin/fenofibrate combination therapy on monocyte release of interleukin-6 and MCP-1 was more pronounced in the male population. The impact of simvastatin administered together with fenofibrate on TNF-alpha, interleukin-1beta, and hsCRP was also stronger in the men than in the women, but the difference did not reach the level of significance.

Conclusions: The obtained results suggest that sex differences determine the strength of the monocyte-suppressing effect of simvastatin/ /fenofibrate combination therapy in type 2 diabetic patients with atherogenic dyslipidaemia. (Endokrynol Pol 2015; 66 (3): 224–230)

Get Citation

Keywords

sex; simvastatin; fenofibrate; atherogenic dyslipidaemia; monocytes; cytokines

About this article
Title

Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.

Journal

Endokrynologia Polska

Issue

Vol 66, No 3 (2015)

Pages

224-230

Published online

2015-07-01

DOI

10.5603/EP.2015.0029

Bibliographic record

Endokrynologia Polska 2015;66(3):224-230.

Keywords

sex
simvastatin
fenofibrate
atherogenic dyslipidaemia
monocytes
cytokines

Authors

Robert Krysiak
Anna Gdula-Dymek
Bogdan Marek
Bogusław Okopień

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl